INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32501, 29963, 'Ziprasidone', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32502, 12802, 'Ziprasidone', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32503, 29963, 'Ziprasidone', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32504, 12802, 'Ziprasidone', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32505, 29963, 'Ziprasidone', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32506, 12802, 'Ziprasidone', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32507, 29963, 'Ziprasidone', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32508, 12802, 'Ziprasidone', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32509, 29963, 'Ziprasidone', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32510, 12802, 'Ziprasidone', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32511, 29963, 'Ziprasidone', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32512, 12802, 'Ziprasidone', 'Priapism', 'Atypical antipsychotic agents with alpha-adrenergic blocking effects may cause priapism.  The condition is characterized by prolonged, often painful erections lasting longer than 4 hours.  If not treated promptly, priapism can cause irreversible damage to the erectile tissue.  Therapy with these agents should be administered cautiously in patients with a history of priapism, conditions that may predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia, thalassemia), or anatomical deformations of the penis (e.g., angulation, cavernosal fibrosis, Peyronie''s disease).  Patients who experience an erection lasting longer than 4 hours, whether painful or not, should immediately discontinue the drug and seek emergency medical attention.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32513, 29963, 'Ziprasidone', 'Priapism', 'Atypical antipsychotic agents with alpha-adrenergic blocking effects may cause priapism.  The condition is characterized by prolonged, often painful erections lasting longer than 4 hours.  If not treated promptly, priapism can cause irreversible damage to the erectile tissue.  Therapy with these agents should be administered cautiously in patients with a history of priapism, conditions that may predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia, thalassemia), or anatomical deformations of the penis (e.g., angulation, cavernosal fibrosis, Peyronie''s disease).  Patients who experience an erection lasting longer than 4 hours, whether painful or not, should immediately discontinue the drug and seek emergency medical attention.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32514, 12802, 'Ziprasidone', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32515, 29963, 'Ziprasidone', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32516, 12802, 'Ziprasidone', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32517, 29963, 'Ziprasidone', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.', '2', '"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32518, 12802, 'Ziprasidone', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32519, 29963, 'Ziprasidone', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'Meco G, Falaschi P, Casacchia M, et al. "Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia." Adv Biochem Psychopharmacol 40 (1985):  89-93|Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH "Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects." Clin Pharmacol Ther 54 (1993):  257-68|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Dickson RA, Dalby JT, Williams R, Edwards AL "Risperidone-induced prolactin elevations in premenopausal women with schizophrenia." Am J Psychiatry 152 (1995):  1102-3|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):|Bai YM, Ciu HJ, Guo ZZ "Risperidone-induced hyperprolactinemia in an elderly woman." Am J Psychiatry 159 (2002):  2112', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32520, 12802, 'Ziprasidone', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32521, 29963, 'Ziprasidone', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD "Pharmacokinetics of thiothixene in man." Clin Pharmacol Ther 16 (1974):  473-8|Hobbs DC "Metabolism of thiothixene." J Pharm Sci 57 (1968):  105-11|Jann MW, Grimsley SR, Gray EC, Chang WH "Pharmacokinetics and pharmacodynamics of clozapine." Clin Pharmacokinet 24 (1993):  161-76|"Product Information. Navane (thiothixene)." Roerig Division  (2001):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32522, 12802, 'Ziprasidone', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32523, 29963, 'Ziprasidone', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32524, 12802, 'Ziprasidone', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32525, 29963, 'Ziprasidone', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32526, 29990, 'Zolpidem', 'Alcoholic Intoxication', 'Anxiolytic, sedative, and hypnotic agents should generally not be given to patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of these agents may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with such agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32527, 29990, 'Zolpidem', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32528, 29990, 'Zolpidem', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', 'Cavallaro R, Regazzetti MG, Covelli G, Smeraldi E "Tolerance and withdrawal with zolpidem." Lancet 342 (1993):  374-5|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Gericke CA, Ludolph AC "Chronic abuse of zolpidem." JAMA 272 (1994):  1721-2|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32529, 29990, 'Zolpidem', 'Liver Diseases', 'Zolpidem is primarily metabolized by the liver.  The plasma concentrations and half-life of zolpidem have been shown to increase substantially in the presence of chronic hepatic insufficiency.  Therapy with zolpidem should be administered cautiously in patients with impaired hepatic function.  Since many of the drug''s adverse effects may be dose-related, especially those involving the central nervous system or gastrointestinal tract, an initial dosage of 5 mg is recommended for these patients.', '3', 'Langtry HD, Benfield P "Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential." Drugs 40 (1990):  291-313|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32530, 29990, 'Zolpidem', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32531, 29990, 'Zolpidem', 'Respiratory Insufficiency', 'Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are recommended.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|Lheureux P, Debailleul G, De Witte O, Askenasi R "Zolpidem intoxication mimicking narcotic overdose: response to flumazenil." Hum Exp Toxicol 9 (1990):  105-7|Murciano D, Aubier M, Palacios S, Parients R "Comparison of zolpidem (Z), triazolam (T), and flunitrazepam (F) effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD)." Chest 97 Suppl (1990):  s51-2|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Biban P, Baraldi E, Pettennazzo A, Filippone M, Zacchello F "Adverse effect of chloral hydrate in two young children with obstructive sleep apnea." Pediatrics 92 (1993):  461-3|Greenberg SB, Faerber EN "Respiratory insufficiency following chloral hydrate sedation in two children with Leigh disease (subacute necrotizing encephalomyelopathy)." Pediatr Radiol 20 (1990):  287-8|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32532, 29990, 'Zolpidem', 'Kidney Diseases', 'Zolpidem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of zolpidem is not altered in the presence of renal insufficiency or even end-stage renal disease, and that there is no accumulation of unchanged drug after repeated dosing.  However, the effects of possible metabolite accumulation have not been studied.  While dosage adjustments are generally not required, close monitoring is recommended in patients with impaired renal function treated with zolpidem.', '2', 'Langtry HD, Benfield P "Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential." Drugs 40 (1990):  291-313|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32533, 1970, 'Bevacizumab', 'Fistula', 'Bevacizumab may cause fatal fistula formation involving tracheoesophageal, bronchopleural, biliary, vaginal, renal and bladder sites.  Permanently discontinue bevacizumab in patients with tracheoesophageal fistula or any Grade 4 fistula.  Discontinue bevacizumab in patients with fistula formation involving an internal organ.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32534, 1974, 'Bevacizumab', 'Fistula', 'Bevacizumab may cause fatal fistula formation involving tracheoesophageal, bronchopleural, biliary, vaginal, renal and bladder sites.  Permanently discontinue bevacizumab in patients with tracheoesophageal fistula or any Grade 4 fistula.  Discontinue bevacizumab in patients with fistula formation involving an internal organ.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32535, 14661, 'Bevacizumab', 'Fistula', 'Bevacizumab may cause fatal fistula formation involving tracheoesophageal, bronchopleural, biliary, vaginal, renal and bladder sites.  Permanently discontinue bevacizumab in patients with tracheoesophageal fistula or any Grade 4 fistula.  Discontinue bevacizumab in patients with fistula formation involving an internal organ.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32536, 14662, 'Bevacizumab', 'Fistula', 'Bevacizumab may cause fatal fistula formation involving tracheoesophageal, bronchopleural, biliary, vaginal, renal and bladder sites.  Permanently discontinue bevacizumab in patients with tracheoesophageal fistula or any Grade 4 fistula.  Discontinue bevacizumab in patients with fistula formation involving an internal organ.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32537, 17310, 'Bevacizumab', 'Fistula', 'Bevacizumab may cause fatal fistula formation involving tracheoesophageal, bronchopleural, biliary, vaginal, renal and bladder sites.  Permanently discontinue bevacizumab in patients with tracheoesophageal fistula or any Grade 4 fistula.  Discontinue bevacizumab in patients with fistula formation involving an internal organ.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32538, 30962, 'Bevacizumab', 'Fistula', 'Bevacizumab may cause fatal fistula formation involving tracheoesophageal, bronchopleural, biliary, vaginal, renal and bladder sites.  Permanently discontinue bevacizumab in patients with tracheoesophageal fistula or any Grade 4 fistula.  Discontinue bevacizumab in patients with fistula formation involving an internal organ.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32539, 30963, 'Bevacizumab', 'Fistula', 'Bevacizumab may cause fatal fistula formation involving tracheoesophageal, bronchopleural, biliary, vaginal, renal and bladder sites.  Permanently discontinue bevacizumab in patients with tracheoesophageal fistula or any Grade 4 fistula.  Discontinue bevacizumab in patients with fistula formation involving an internal organ.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32540, 1970, 'Bevacizumab', 'Peptic Ulcer Perforation', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) may cause gastrointestinal perforation and fistulae.  Avoid use of these agents in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction.  Permanently discontinue these agents in patients with gastrointestinal perforation.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32541, 1974, 'Bevacizumab', 'Peptic Ulcer Perforation', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) may cause gastrointestinal perforation and fistulae.  Avoid use of these agents in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction.  Permanently discontinue these agents in patients with gastrointestinal perforation.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32542, 14661, 'Bevacizumab', 'Peptic Ulcer Perforation', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) may cause gastrointestinal perforation and fistulae.  Avoid use of these agents in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction.  Permanently discontinue these agents in patients with gastrointestinal perforation.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32543, 14662, 'Bevacizumab', 'Peptic Ulcer Perforation', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) may cause gastrointestinal perforation and fistulae.  Avoid use of these agents in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction.  Permanently discontinue these agents in patients with gastrointestinal perforation.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32544, 17310, 'Bevacizumab', 'Peptic Ulcer Perforation', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) may cause gastrointestinal perforation and fistulae.  Avoid use of these agents in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction.  Permanently discontinue these agents in patients with gastrointestinal perforation.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32545, 30962, 'Bevacizumab', 'Peptic Ulcer Perforation', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) may cause gastrointestinal perforation and fistulae.  Avoid use of these agents in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction.  Permanently discontinue these agents in patients with gastrointestinal perforation.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32546, 30963, 'Bevacizumab', 'Peptic Ulcer Perforation', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) may cause gastrointestinal perforation and fistulae.  Avoid use of these agents in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction.  Permanently discontinue these agents in patients with gastrointestinal perforation.', '3', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32547, 1970, 'Bevacizumab', 'Hemorrhage', 'Bevacizumab impairs wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Bevacizumab should not be started for at least 28 days after surgery and until the wound is fully healed.  Discontinue bevacizumab in patients with wound healing complications requiring medical intervention or in patients who develop necrotizing fasciitis.  Do not administer this agent to patients with recent history of hemoptysis and discontinue bevacizumab in patients with hemorrhage.  Caution is recommended when using this agent in patients at increased risk of bleeding or before surgery and is recommended to stop therapy for at least 28 days prior to elective surgery.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32548, 1974, 'Bevacizumab', 'Hemorrhage', 'Bevacizumab impairs wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Bevacizumab should not be started for at least 28 days after surgery and until the wound is fully healed.  Discontinue bevacizumab in patients with wound healing complications requiring medical intervention or in patients who develop necrotizing fasciitis.  Do not administer this agent to patients with recent history of hemoptysis and discontinue bevacizumab in patients with hemorrhage.  Caution is recommended when using this agent in patients at increased risk of bleeding or before surgery and is recommended to stop therapy for at least 28 days prior to elective surgery.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32549, 14661, 'Bevacizumab', 'Hemorrhage', 'Bevacizumab impairs wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Bevacizumab should not be started for at least 28 days after surgery and until the wound is fully healed.  Discontinue bevacizumab in patients with wound healing complications requiring medical intervention or in patients who develop necrotizing fasciitis.  Do not administer this agent to patients with recent history of hemoptysis and discontinue bevacizumab in patients with hemorrhage.  Caution is recommended when using this agent in patients at increased risk of bleeding or before surgery and is recommended to stop therapy for at least 28 days prior to elective surgery.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32550, 14662, 'Bevacizumab', 'Hemorrhage', 'Bevacizumab impairs wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Bevacizumab should not be started for at least 28 days after surgery and until the wound is fully healed.  Discontinue bevacizumab in patients with wound healing complications requiring medical intervention or in patients who develop necrotizing fasciitis.  Do not administer this agent to patients with recent history of hemoptysis and discontinue bevacizumab in patients with hemorrhage.  Caution is recommended when using this agent in patients at increased risk of bleeding or before surgery and is recommended to stop therapy for at least 28 days prior to elective surgery.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32551, 17310, 'Bevacizumab', 'Hemorrhage', 'Bevacizumab impairs wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Bevacizumab should not be started for at least 28 days after surgery and until the wound is fully healed.  Discontinue bevacizumab in patients with wound healing complications requiring medical intervention or in patients who develop necrotizing fasciitis.  Do not administer this agent to patients with recent history of hemoptysis and discontinue bevacizumab in patients with hemorrhage.  Caution is recommended when using this agent in patients at increased risk of bleeding or before surgery and is recommended to stop therapy for at least 28 days prior to elective surgery.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32552, 30962, 'Bevacizumab', 'Hemorrhage', 'Bevacizumab impairs wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Bevacizumab should not be started for at least 28 days after surgery and until the wound is fully healed.  Discontinue bevacizumab in patients with wound healing complications requiring medical intervention or in patients who develop necrotizing fasciitis.  Do not administer this agent to patients with recent history of hemoptysis and discontinue bevacizumab in patients with hemorrhage.  Caution is recommended when using this agent in patients at increased risk of bleeding or before surgery and is recommended to stop therapy for at least 28 days prior to elective surgery.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32553, 30963, 'Bevacizumab', 'Hemorrhage', 'Bevacizumab impairs wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Bevacizumab should not be started for at least 28 days after surgery and until the wound is fully healed.  Discontinue bevacizumab in patients with wound healing complications requiring medical intervention or in patients who develop necrotizing fasciitis.  Do not administer this agent to patients with recent history of hemoptysis and discontinue bevacizumab in patients with hemorrhage.  Caution is recommended when using this agent in patients at increased risk of bleeding or before surgery and is recommended to stop therapy for at least 28 days prior to elective surgery.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32554, 1970, 'Bevacizumab', 'Hypertension', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) have been associated with severe increases in blood pressure.  Therapy with these agents should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment, regularly during treatment and after discontinuation in patients with bevacizumab -induced or -exacerbated hypertension.  Temporarily suspend these agents in patients with severe hypertension that is not controlled with medical management.  Discontinue these agents in patients with hypertensive crisis or hypertensive encephalopathy.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32555, 1974, 'Bevacizumab', 'Hypertension', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) have been associated with severe increases in blood pressure.  Therapy with these agents should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment, regularly during treatment and after discontinuation in patients with bevacizumab -induced or -exacerbated hypertension.  Temporarily suspend these agents in patients with severe hypertension that is not controlled with medical management.  Discontinue these agents in patients with hypertensive crisis or hypertensive encephalopathy.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32556, 14661, 'Bevacizumab', 'Hypertension', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) have been associated with severe increases in blood pressure.  Therapy with these agents should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment, regularly during treatment and after discontinuation in patients with bevacizumab -induced or -exacerbated hypertension.  Temporarily suspend these agents in patients with severe hypertension that is not controlled with medical management.  Discontinue these agents in patients with hypertensive crisis or hypertensive encephalopathy.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32557, 14662, 'Bevacizumab', 'Hypertension', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) have been associated with severe increases in blood pressure.  Therapy with these agents should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment, regularly during treatment and after discontinuation in patients with bevacizumab -induced or -exacerbated hypertension.  Temporarily suspend these agents in patients with severe hypertension that is not controlled with medical management.  Discontinue these agents in patients with hypertensive crisis or hypertensive encephalopathy.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32558, 17310, 'Bevacizumab', 'Hypertension', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) have been associated with severe increases in blood pressure.  Therapy with these agents should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment, regularly during treatment and after discontinuation in patients with bevacizumab -induced or -exacerbated hypertension.  Temporarily suspend these agents in patients with severe hypertension that is not controlled with medical management.  Discontinue these agents in patients with hypertensive crisis or hypertensive encephalopathy.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32559, 30962, 'Bevacizumab', 'Hypertension', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) have been associated with severe increases in blood pressure.  Therapy with these agents should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment, regularly during treatment and after discontinuation in patients with bevacizumab -induced or -exacerbated hypertension.  Temporarily suspend these agents in patients with severe hypertension that is not controlled with medical management.  Discontinue these agents in patients with hypertensive crisis or hypertensive encephalopathy.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32560, 30963, 'Bevacizumab', 'Hypertension', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) have been associated with severe increases in blood pressure.  Therapy with these agents should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment, regularly during treatment and after discontinuation in patients with bevacizumab -induced or -exacerbated hypertension.  Temporarily suspend these agents in patients with severe hypertension that is not controlled with medical management.  Discontinue these agents in patients with hypertensive crisis or hypertensive encephalopathy.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32561, 1970, 'Bevacizumab', 'Posterior Leukoencephalopathy Syndrome', 'Posterior Reversible Encephalopathy Syndrome (PRES) has been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR) in clinical studies.  PRES is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.  It is recommended to discontinue these agents in patients developing PRES.  The safety of restarting therapy is not known.  Cation is recommended if therapy is reinitiating in patients previously experiencing PRES.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32562, 1974, 'Bevacizumab', 'Posterior Leukoencephalopathy Syndrome', 'Posterior Reversible Encephalopathy Syndrome (PRES) has been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR) in clinical studies.  PRES is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.  It is recommended to discontinue these agents in patients developing PRES.  The safety of restarting therapy is not known.  Cation is recommended if therapy is reinitiating in patients previously experiencing PRES.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32563, 14661, 'Bevacizumab', 'Posterior Leukoencephalopathy Syndrome', 'Posterior Reversible Encephalopathy Syndrome (PRES) has been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR) in clinical studies.  PRES is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.  It is recommended to discontinue these agents in patients developing PRES.  The safety of restarting therapy is not known.  Cation is recommended if therapy is reinitiating in patients previously experiencing PRES.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32564, 14662, 'Bevacizumab', 'Posterior Leukoencephalopathy Syndrome', 'Posterior Reversible Encephalopathy Syndrome (PRES) has been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR) in clinical studies.  PRES is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.  It is recommended to discontinue these agents in patients developing PRES.  The safety of restarting therapy is not known.  Cation is recommended if therapy is reinitiating in patients previously experiencing PRES.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32565, 17310, 'Bevacizumab', 'Posterior Leukoencephalopathy Syndrome', 'Posterior Reversible Encephalopathy Syndrome (PRES) has been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR) in clinical studies.  PRES is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.  It is recommended to discontinue these agents in patients developing PRES.  The safety of restarting therapy is not known.  Cation is recommended if therapy is reinitiating in patients previously experiencing PRES.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32566, 30962, 'Bevacizumab', 'Posterior Leukoencephalopathy Syndrome', 'Posterior Reversible Encephalopathy Syndrome (PRES) has been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR) in clinical studies.  PRES is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.  It is recommended to discontinue these agents in patients developing PRES.  The safety of restarting therapy is not known.  Cation is recommended if therapy is reinitiating in patients previously experiencing PRES.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32567, 30963, 'Bevacizumab', 'Posterior Leukoencephalopathy Syndrome', 'Posterior Reversible Encephalopathy Syndrome (PRES) has been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR) in clinical studies.  PRES is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.  It is recommended to discontinue these agents in patients developing PRES.  The safety of restarting therapy is not known.  Cation is recommended if therapy is reinitiating in patients previously experiencing PRES.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32568, 1970, 'Bevacizumab', 'Proteinuria', 'The incidence and severity of proteinuria is increased in patients taking inhibitors of vascular endothelial growth factor receptors (VEGFR).  Therapy with these agents should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  It is recommended to temporarily suspend these agents in patients with moderate to severe proteinuria and to discontinue therapy in patients with nephrotic syndrome.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32569, 1974, 'Bevacizumab', 'Proteinuria', 'The incidence and severity of proteinuria is increased in patients taking inhibitors of vascular endothelial growth factor receptors (VEGFR).  Therapy with these agents should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  It is recommended to temporarily suspend these agents in patients with moderate to severe proteinuria and to discontinue therapy in patients with nephrotic syndrome.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32570, 14661, 'Bevacizumab', 'Proteinuria', 'The incidence and severity of proteinuria is increased in patients taking inhibitors of vascular endothelial growth factor receptors (VEGFR).  Therapy with these agents should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  It is recommended to temporarily suspend these agents in patients with moderate to severe proteinuria and to discontinue therapy in patients with nephrotic syndrome.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32571, 14662, 'Bevacizumab', 'Proteinuria', 'The incidence and severity of proteinuria is increased in patients taking inhibitors of vascular endothelial growth factor receptors (VEGFR).  Therapy with these agents should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  It is recommended to temporarily suspend these agents in patients with moderate to severe proteinuria and to discontinue therapy in patients with nephrotic syndrome.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32572, 17310, 'Bevacizumab', 'Proteinuria', 'The incidence and severity of proteinuria is increased in patients taking inhibitors of vascular endothelial growth factor receptors (VEGFR).  Therapy with these agents should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  It is recommended to temporarily suspend these agents in patients with moderate to severe proteinuria and to discontinue therapy in patients with nephrotic syndrome.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32573, 30962, 'Bevacizumab', 'Proteinuria', 'The incidence and severity of proteinuria is increased in patients taking inhibitors of vascular endothelial growth factor receptors (VEGFR).  Therapy with these agents should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  It is recommended to temporarily suspend these agents in patients with moderate to severe proteinuria and to discontinue therapy in patients with nephrotic syndrome.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32574, 30963, 'Bevacizumab', 'Proteinuria', 'The incidence and severity of proteinuria is increased in patients taking inhibitors of vascular endothelial growth factor receptors (VEGFR).  Therapy with these agents should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  It is recommended to temporarily suspend these agents in patients with moderate to severe proteinuria and to discontinue therapy in patients with nephrotic syndrome.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32575, 1970, 'Bevacizumab', 'Thromboembolism', 'Venous and arterial thromboembolic events (VTE and ATE), some fatal, have been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR).  Caution is recommended when using these agents in patients with a reported history of VTE or ATE.  These agents should be discontinued in patients with serious or life-threatening VTE or ATE, including pulmonary embolism.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32576, 1974, 'Bevacizumab', 'Thromboembolism', 'Venous and arterial thromboembolic events (VTE and ATE), some fatal, have been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR).  Caution is recommended when using these agents in patients with a reported history of VTE or ATE.  These agents should be discontinued in patients with serious or life-threatening VTE or ATE, including pulmonary embolism.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32577, 14661, 'Bevacizumab', 'Thromboembolism', 'Venous and arterial thromboembolic events (VTE and ATE), some fatal, have been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR).  Caution is recommended when using these agents in patients with a reported history of VTE or ATE.  These agents should be discontinued in patients with serious or life-threatening VTE or ATE, including pulmonary embolism.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32578, 14662, 'Bevacizumab', 'Thromboembolism', 'Venous and arterial thromboembolic events (VTE and ATE), some fatal, have been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR).  Caution is recommended when using these agents in patients with a reported history of VTE or ATE.  These agents should be discontinued in patients with serious or life-threatening VTE or ATE, including pulmonary embolism.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32579, 17310, 'Bevacizumab', 'Thromboembolism', 'Venous and arterial thromboembolic events (VTE and ATE), some fatal, have been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR).  Caution is recommended when using these agents in patients with a reported history of VTE or ATE.  These agents should be discontinued in patients with serious or life-threatening VTE or ATE, including pulmonary embolism.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32580, 30962, 'Bevacizumab', 'Thromboembolism', 'Venous and arterial thromboembolic events (VTE and ATE), some fatal, have been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR).  Caution is recommended when using these agents in patients with a reported history of VTE or ATE.  These agents should be discontinued in patients with serious or life-threatening VTE or ATE, including pulmonary embolism.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32581, 30963, 'Bevacizumab', 'Thromboembolism', 'Venous and arterial thromboembolic events (VTE and ATE), some fatal, have been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR).  Caution is recommended when using these agents in patients with a reported history of VTE or ATE.  These agents should be discontinued in patients with serious or life-threatening VTE or ATE, including pulmonary embolism.', '2', '"Product Information. Avastin (bevacizumab)." Genentech  (2004):|"Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):|"Product Information. Cyramza (ramucirumab)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32582, 0, 'Bethanechol', 'Bronchial Spasm', 'The use of cholinergic agonists is contraindicated in patients with uncontrolled reactive airway disease.  Cholinergic agonists inhibits the hydrolysis of acetylcholine.  The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm.', '3', '"Product Information. Salagen (pilocarpine)." Boehringer-Ingelheim|"Product Information. Urecholine (bethanechol)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32583, 0, 'Bethanechol', 'Heart Failure', 'The use of cholinergic agonists, such as bethanechol and pilocarpine, is contraindicated in patients with pronounced bradycardia, hypotension/hypertension, coronary artery disease or conduction disorders.', '3', '"Product Information. Salagen (pilocarpine)." Boehringer-Ingelheim|"Product Information. Urecholine (bethanechol)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32584, 0, 'Bethanechol', 'Urinary Bladder Neck Obstruction', 'The use of cholinergic agonists is contraindicated in patients with peptic ulcers, mechanical GI obstruction, acute GI inflammatory conditions, or urinary obstruction.  Cholinergic activity may result in an increase in gastric acid secretion, GI motility, and gastric contractions.  In patients with urinary retention, urinary reflux may occur if the sphincter fails to relax when the bladder is contracted by cholinergic stimulation.  The reflux of urine from the bladder can cause infection in the kidneys and upper urinary tract if bacteriuria is present.', '3', '"Product Information. Salagen (pilocarpine)." Boehringer-Ingelheim|"Product Information. Urecholine (bethanechol)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32585, 0, 'Bethanechol', 'Hyperthyroidism', 'The use of cholinergic agents may be contraindicated in patients with hyperthyroidism.  Atrial fibrillation has occurred in hyperthyroid patients administered a cholinergic agonist.', '3', '"Product Information. Salagen (pilocarpine)." Boehringer-Ingelheim|"Product Information. Urecholine (bethanechol)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32586, 0, 'Bethanechol', 'Parkinsonian Disorders', 'The use of cholinergic agonists may be contraindicated in patients with parkinsonism.  Cholinergic agonists directly stimulates the parasympathetic nervous system inducing acetylcholinergic effects.  Symptoms of Parkinson''s disease may be exacerbated.', '3', '"Product Information. Salagen (pilocarpine)." Boehringer-Ingelheim|"Product Information. Urecholine (bethanechol)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32587, 0, 'Bethanechol', 'Epilepsy', 'The use of cholinergic agonists may be contraindicated in patients with seizure disorders.  Cholinomimetics have been associated with convulsions.', '3', '"Product Information. Salagen (pilocarpine)." Boehringer-Ingelheim|"Product Information. Urecholine (bethanechol)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32588, 222, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32589, 1025, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32590, 1027, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32591, 1028, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32592, 1030, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32593, 2075, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32594, 4575, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32595, 4576, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32596, 9922, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32597, 9923, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32598, 9924, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32599, 12983, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32600, 13018, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32601, 13383, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32602, 14472, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32603, 14484, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32604, 14485, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32605, 14490, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32606, 14492, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32607, 14493, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32608, 14494, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32609, 14498, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32610, 26212, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'Moroz LA "Increased blood fibrinolytic activity after aspirin ingestion." N Engl J Med 296 (1977):  525-9|Garg SK, Sarker CR "Aspirin-induced thrombocytopenia on an immune basis." Am J Med Sci 267 (1974):  129-32|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV "Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function." Eur J Clin Pharmacol 35 (1988):  287-94|Patrono C "Aspirin as an antiplatelet drug." N Engl J Med 330 (1994):  1287-94|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Ferraris VA, Ferraris SP "Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting - update." Ann Thorac Surg 59 (1995):  1036-7|Buerke M, Pittroff W, Meyer J, Darius H "Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses." Am Heart J 130 (1995):  465-72|Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G "Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects." Chest 108 Suppl (1995):  s247-57|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|He J, Whelton PK, Vu B, Klag MJ "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials." JAMA 280 (1998):  1930-35|Petty GW, Brown RD, Whisnant JP, Sicks JD, O''Fallon WM, Wiebers DO "Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population study." Ann Intern Med 130 (1999):  14-22|"Product Information. Bayer Aspirin (acetylsalicylsyra)." Bayer|Colwell JA "Aspirin and risk of hemorrhagic stroke." JAMA 282 (1999):  731-2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32611, 222, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32612, 1025, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32613, 1027, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32614, 1028, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32615, 1030, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32616, 2075, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32617, 4575, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32618, 4576, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32619, 9922, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32620, 9923, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32621, 9924, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32622, 12983, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32623, 13018, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32624, 13383, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32625, 14472, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32626, 14484, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32627, 14485, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32628, 14490, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32629, 14492, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32630, 14493, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32631, 14494, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32632, 14498, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32633, 26212, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32634, 222, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32635, 1025, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32636, 1027, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32637, 1028, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32638, 1030, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32639, 2075, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32640, 4575, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32641, 4576, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32642, 9922, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32643, 9923, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32644, 9924, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32645, 12983, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32646, 13018, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32647, 13383, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32648, 14472, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32649, 14484, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32650, 14485, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32651, 14490, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32652, 14492, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32653, 14493, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32654, 14494, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32655, 14498, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32656, 26212, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992):  685-8|Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992):  996-1000|Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Sabesin SM, Boyce HW Jr, King CE, Mann JA, Ruoff G, Wall E "Comparative evaluation of gastrointestinal intolerance produced by plain and tri-buffered aspirin tablets." Am J Gastroenterol 83 (1988):  1220-5|Graham DY, Smith JL "Aspirin and the stomach." Ann Intern Med 104 (1986):  390-8|Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988):  281-5|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Roderick PJ, Wilkes HC, Meade TW "The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials." Br J Clin Pharmacol 35 (1993):  219-26|Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994):  42-6|Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K "Adverse effects of low-dose aspirin in a healthy elderly population." Clin Pharmacol Ther 54 (1993):  84-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Weil J, Colinjones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P "Prophylactic aspirin and risk of peptic ulcer bleeding." BMJ 310 (1995):  827-30|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604|Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R "Evidence of aspirin use in both upper and lower gastrointestinal perforation." Gastroenterology 112 (1997):  683-9', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32657, 222, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32658, 1025, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32659, 1027, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32660, 1028, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32661, 1030, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32662, 2075, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32663, 4575, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32664, 4576, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32665, 9922, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32666, 9923, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32667, 9924, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32668, 12983, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32669, 13018, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32670, 13383, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32671, 14472, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32672, 14484, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32673, 14485, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32674, 14490, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32675, 14492, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32676, 14493, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32677, 14494, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32678, 14498, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32679, 26212, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'Kimberly RP, Plotz PH "Aspirin-induced depression of renal function." N Engl J Med 296 (1977):  418-24|Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K "Effects of acetylsalicylic acid on renal function in patients with chronic heart failure." Am J Med 90 (1991):  571-5|Carmichael J, Shankel SW "Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function." Am J Med 78 (1985):  992-1000|Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD "Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs." Am J Kidney Dis 20 (1992):  281-5|Maher JF "Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America." Am J Med 76 (1984):  345-8|Muther RS, Potter DM, Bennett WM "Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance." Ann Intern Med 94 (1981):  317-21|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Whelton A "Renal effects of over-the-counter analgesics." J Clin Pharmacol 35 (1995):  454-63|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32680, 222, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32681, 1025, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32682, 1027, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32683, 1028, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32684, 1030, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32685, 2075, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32686, 4575, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32687, 4576, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32688, 9922, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32689, 9923, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32690, 9924, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32691, 12983, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32692, 13018, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32693, 13383, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32694, 14472, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32695, 14484, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32696, 14485, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32697, 14490, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32698, 14492, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32699, 14493, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32700, 14494, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32701, 14498, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32702, 26212, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'Epidemiology Office, Divisiion of Viral and Rickettsial Diseasses, Center for Infectious Diseases, Centers for Disease Control. "Leads from the MMWR. Reye syndrome surveillance--United States, 1987 and 1988." JAMA 261 (1989):  3520,|Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982):  167|"Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Arvin A, Kliegman R, Nelson W, Behrman R, eds. "Nelson Textbook of Pediatrics." Philadelphia, PA: W.B. Saunders Company  (1996):|American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics  (1997):|Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB "Reye''s syndrome in the United States from 1981 through 1997." N Engl J Med 340 (1999):  1377-82|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32703, 222, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32704, 1025, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32705, 1027, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32706, 1028, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32707, 1030, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32708, 2075, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32709, 4575, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32710, 4576, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32711, 9922, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32712, 9923, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32713, 9924, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32714, 12983, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32715, 13018, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32716, 13383, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32717, 14472, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32718, 14484, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32719, 14485, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32720, 14490, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32721, 14492, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32722, 14493, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32723, 14494, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32724, 14498, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32725, 26212, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'Naschitz JE, Yeshurun D, Odeh M, Bassan H, Rosner I, Stermer E, Levy N "Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease." Am J Gastroenterol 85 (1990):  408-11|Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ "Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin." BMJ 298 (1989):  493-6|Savon JJ, Allen ML, Dimarino AJ, Hermann GA, Krum RP "Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration." Am J Gastroenterol 90 (1995):  581-5|Stalnikowiczdarvasi R "Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis." J Clin Gastroenterol 21 (1995):  13-6|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|Marks RD "Aspirin use and fecal occult blood testing." Am J Med 100 (1996):  596-7|Greenberg PD, Cello JP, Rockey DC "Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease." Am J Med 100 (1996):  598-604', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32726, 222, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32727, 1025, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32728, 1027, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32729, 1028, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32730, 1030, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32731, 2075, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32732, 4575, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32733, 4576, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32734, 9922, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32735, 9923, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32736, 9924, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32737, 12983, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32738, 13018, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32739, 13383, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32740, 14472, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32741, 14484, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32742, 14485, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32743, 14490, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32744, 14492, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32745, 14493, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32746, 14494, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32747, 14498, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32748, 26212, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32749, 222, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32750, 1025, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32751, 1027, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32752, 1028, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32753, 1030, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32754, 2075, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32755, 4575, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32756, 4576, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32757, 9922, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32758, 9923, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32759, 9924, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32760, 12983, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32761, 13018, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32762, 13383, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32763, 14472, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32764, 14484, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32765, 14485, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32766, 14490, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32767, 14492, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32768, 14493, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32769, 14494, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32770, 14498, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32771, 26212, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Ecotrin (aspirin)." SmithKline Beecham  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32772, 222, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32773, 1025, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32774, 1027, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32775, 1028, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32776, 1030, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32777, 2075, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32778, 4575, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32779, 4576, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32780, 9922, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32781, 9923, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32782, 9924, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32783, 12983, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32784, 13018, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32785, 13383, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32786, 14472, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32787, 14484, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32788, 14485, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32789, 14490, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32790, 14492, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32791, 14493, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32792, 14494, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32793, 14498, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32794, 26212, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'Seaman WE, Ishak KG, Plotz PH "Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus." Ann Intern Med 80 (1974):  1-8|Wolfe JD, Metzger AL, Goldstein RC "Aspirin hepatitis." Ann Intern Med 80 (1974):  74-6|Sbarbaro JA, Bennett RM "Aspirin hepatotoxicity and disseminated intravascular coagulation." Ann Intern Med 86 (1977):  183-5|Jorup-Ronstrom C, Beermann B, Wahlin-Boll E, Melander A, Britton S "Reduction of paracetamol and aspirin metabolism during viral hepatitis." Clin Pharmacokinet 11 (1986):  250-6|Patel DK, Hesse A, Ogunbona A, Notarianni LJ, Bennett PN "Metabolism of aspirin after therapeutic and toxic doses." Hum Exp Toxicol 9 (1990):  131-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Salflex (salsalate)." Carnrick Laboratories Inc  (2001):|"Product Information. Rexolate (sodium thiosalicylate)." Hyrex Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32795, 0, 'Betrixaban', 'Hemorrhage', 'The use of betrixaban is contraindicated in patients with active pathological bleeding.  Care and close monitoring is recommended when using this agent in patients who are receiving neuraxial anesthesia or undergoing spinal puncture as epidural or spinal hematomas may occur.  Consider risk of using this agent when scheduling patients for spinal procedures.', '3', '"Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32796, 0, 'Betrixaban', 'Liver Diseases', 'The use of betrixaban is not recommended in patients with hepatic impairment as these patients may have intrinsic coagulation abnormalities.', '3', '"Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32797, 0, 'Betrixaban', 'Kidney Diseases', 'Patients with severe renal impairment (CrCl >= 15 to < 30 mL/min computed by Cockcroft-Gault using actual body weight) may have an increased risk of bleeding events.  It is recommended to reduce the betrixaban dose in patients with severe renal impairment.  Monitor patients closely and promptly evaluate any signs or symptoms of blood loss in these patients.  No dose adjustment is needed for mild or moderate renal impairment (CrCl > 30 mL/min, computed by Cockcroft-Gault using actual body weight).', '3', '"Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32798, 0, 'Betrixaban', 'Antiphospholipid Syndrome', 'Direct acting oral anticoagulants including factor Xa inhibitors and some thrombin inhibitors as dabigatran, are not recommended for use in patients with antiphospholipid syndrome (APS).  Treatment with these drugs has been associated with increased rates of recurrent thrombotic events, especially in patients with triple positive APS.', '2', '"Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim  (2010):|"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32799, 0, 'Abaloparatide', 'Hyperparathyroidism', 'Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with parathyroid hormone and its analogs because of the risk of exacerbating hypercalcemia.', '3', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):|"Product Information. Natpara (parathyroid hormone)." NPS Pharmaceuticals  (2015):|"Product Information. Tymlos (abaloparatide)." Radius Health  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32800, 0, 'Abaloparatide', 'Neoplasms', 'Parathyroid hormone and its analogs should not be used in patients who are at increased baseline risk for osteosarcoma.  These agents should only be used if the potential benefits are considered to outweigh the potential risks.  Monitor these patients according to clinical guidelines.  Patients with bone metastases or a history of skeletal malignancies should not be treated with these agents.', '3', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):|"Product Information. Natpara (parathyroid hormone)." NPS Pharmaceuticals  (2015):|"Product Information. Tymlos (abaloparatide)." Radius Health  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32801, 0, 'Abaloparatide', 'Urolithiasis', 'No dosage adjustment is required for patients with mild, moderate, or severe renal impairment.  Patients with severe renal impairment may have increased abaloparatide exposure that may increase the risk of adverse reactions; therefore, monitor for adverse reactions.  Abaloparatide may exacerbate urolithiasis in patients with active or a history of urolithiasis.  If active urolithiasis or preexisting hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.', '2', '"Product Information. Tymlos (abaloparatide)." Radius Health  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32802, 15926, 'Bicalutamide', 'Liver Diseases', 'Bicalutamide is extensively metabolized by the liver and its metabolism may be altered and/or delayed in patients with moderate to severe hepatic impairment.  Therapy with bicalutamide should be administered cautiously in patients with moderate to severe hepatic impairment.  Additionally there have been postmarketing reports of death or hospitalization due to severe liver injury (hepatic failure) in association with bicalutamide, so extra caution is advised in patients with hepatic impairment.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Clinical monitoring of hepatic function is recommended.  Although hepatic abnormalities such as elevated liver transaminase levels and jaundice are usually reversible, bicalutamide therapy should be discontinued if transaminase levels exceed two times the upper normal limits.', '2', '"Product Information. Casodex (bicalutamide)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32803, 30186, 'Bicalutamide', 'Liver Diseases', 'Bicalutamide is extensively metabolized by the liver and its metabolism may be altered and/or delayed in patients with moderate to severe hepatic impairment.  Therapy with bicalutamide should be administered cautiously in patients with moderate to severe hepatic impairment.  Additionally there have been postmarketing reports of death or hospitalization due to severe liver injury (hepatic failure) in association with bicalutamide, so extra caution is advised in patients with hepatic impairment.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Clinical monitoring of hepatic function is recommended.  Although hepatic abnormalities such as elevated liver transaminase levels and jaundice are usually reversible, bicalutamide therapy should be discontinued if transaminase levels exceed two times the upper normal limits.', '2', '"Product Information. Casodex (bicalutamide)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32804, 31817, 'Bicalutamide', 'Liver Diseases', 'Bicalutamide is extensively metabolized by the liver and its metabolism may be altered and/or delayed in patients with moderate to severe hepatic impairment.  Therapy with bicalutamide should be administered cautiously in patients with moderate to severe hepatic impairment.  Additionally there have been postmarketing reports of death or hospitalization due to severe liver injury (hepatic failure) in association with bicalutamide, so extra caution is advised in patients with hepatic impairment.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Clinical monitoring of hepatic function is recommended.  Although hepatic abnormalities such as elevated liver transaminase levels and jaundice are usually reversible, bicalutamide therapy should be discontinued if transaminase levels exceed two times the upper normal limits.', '2', '"Product Information. Casodex (bicalutamide)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32805, 33143, 'Bicalutamide', 'Liver Diseases', 'Bicalutamide is extensively metabolized by the liver and its metabolism may be altered and/or delayed in patients with moderate to severe hepatic impairment.  Therapy with bicalutamide should be administered cautiously in patients with moderate to severe hepatic impairment.  Additionally there have been postmarketing reports of death or hospitalization due to severe liver injury (hepatic failure) in association with bicalutamide, so extra caution is advised in patients with hepatic impairment.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Clinical monitoring of hepatic function is recommended.  Although hepatic abnormalities such as elevated liver transaminase levels and jaundice are usually reversible, bicalutamide therapy should be discontinued if transaminase levels exceed two times the upper normal limits.', '2', '"Product Information. Casodex (bicalutamide)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32806, 1485, 'Betaxolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32807, 14314, 'Betaxolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32808, 15147, 'Betaxolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32809, 15148, 'Betaxolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32810, 15162, 'Betaxolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32811, 15163, 'Betaxolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32812, 15177, 'Betaxolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32813, 15178, 'Betaxolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32814, 18465, 'Betaxolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32815, 25194, 'Betaxolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'van Zyl AI, Jennings AA, Bateman ED, Opie LH "Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension." Chest 95 (1989):  209-13|Adam WR, Meagher EJ, Barter CE "Labetalol, beta blockers, and acute deterioration of chronic airway obstruction." Clin Exp Hypertens A A4 (1982):  1419-28|Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986):  251-60|Durant PA, Joucken K "Bronchospasm and hypotension during cardiopulmonary bypass after preoperative cimetidine and labetalol therapy." Br J Anaesth 56 (1984):  917-20|Raine JM, Palazzo MG, Kerr JH, Sleight P "Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane." Br Med J 282 (1981):  548-9|Stephen SA "Unwanted effects of propranolol." Am J Cardiol 18 (1966):  463-72|Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988):  s18-24|Morris R, Bulteau P "Respiratory arrest after beta-blocker in an asthmatic patient." Med J Aust 2 (1980):  576|Charan NB, Lakshminarayan S "Pulmonary effects of topical timolol." Arch Intern Med 140 (1980):  843-4|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Laursen SO, Bjerrum P "Timolol eyedrop-induced severe bronchospasm." Acta Med Scand 211 (1982):  505-6|Prince DS, Carliner NH "Respiratory arrest following first dose of timolol ophthalmic solution." Chest 84 (1983):  640-1|Botet C, Grau J, Benito P, Coll J, Vivancos J "Timolol ophthalmic solution and respiratory arrest." Ann Intern Med 105 (1986):  306-7|Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986):  264-8|Odeh M, Oliven A, Bassan H "Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient." J Fam Pract 32 (1991):  97-8|Schoenberger JA, Croog SH, Sudilovsky A, et al. "Self-reported side effects from antihypertensive drugs: a clinical trial." Am J Hypertens 3 (1990):  123-32|Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R "A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension." Aust N Z J Med 8 (1978):  1-6|Benson MK, Berrill WT, Cruickshank JM, Sterling GS "A comparison of four B-adrenoceptor antagonists in patients with asthma." Br J Clin Pharmacol 5 (1978):  415-9|Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L "Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol." J Clin Pharmacol 29 (1989):  97-101|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32816, 1485, 'Betaxolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32817, 14314, 'Betaxolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32818, 15147, 'Betaxolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32819, 15148, 'Betaxolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32820, 15162, 'Betaxolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32821, 15163, 'Betaxolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32822, 15177, 'Betaxolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32823, 15178, 'Betaxolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32824, 18465, 'Betaxolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32825, 25194, 'Betaxolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32826, 1485, 'Betaxolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32827, 14314, 'Betaxolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32828, 15147, 'Betaxolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32829, 15148, 'Betaxolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32830, 15162, 'Betaxolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32831, 15163, 'Betaxolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32832, 15177, 'Betaxolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32833, 15178, 'Betaxolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32834, 18465, 'Betaxolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32835, 25194, 'Betaxolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'Kholeif M, Isles C "Profound hypotension after atenolol in severe hypertension." Br Med J 298 (1989):  161-2|Tirlapur VG, Evans PJ, Jones MK "Shock syndrome after acebutolol." Br J Clin Pract 40 (1986):  33-4|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32836, 1485, 'Betaxolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32837, 14314, 'Betaxolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32838, 15147, 'Betaxolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32839, 15148, 'Betaxolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32840, 15162, 'Betaxolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32841, 15163, 'Betaxolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32842, 15177, 'Betaxolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32843, 15178, 'Betaxolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32844, 18465, 'Betaxolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32845, 25194, 'Betaxolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'Altus P "Timolol-induced congestive heart failure." South Med J 74 (1981):  88|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32846, 1485, 'Betaxolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32847, 14314, 'Betaxolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32848, 15147, 'Betaxolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32849, 15148, 'Betaxolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32850, 15162, 'Betaxolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32851, 15163, 'Betaxolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32852, 15177, 'Betaxolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32853, 15178, 'Betaxolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32854, 18465, 'Betaxolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32855, 25194, 'Betaxolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'Darga LL, Hakim MJ, Lucas CP, Franklin BA "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol 67 (1991):  590-6|Uusitupa M, Aro A, Pietikainen M "Severe hypoglycaemia caused by physical strain and pindolol therapy." Ann Clin Res 12 (1980):  25-7|Velde TM, Kaiser FE "Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient." Arch Intern Med 143 (1983):  1627|Grimaldi A, Bennett P, Delas B, et al. "Beta-blockers and hypoglycaemia: assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia." Curr Ther Res Clin Exp 36 (1984):  361-73|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|Giugliano D, Acampora R, Marfella R, DeRosa N, Ziccardi P, Ragone R, DeAngelis L, DOnofrio F "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial." Ann Intern Med 126 (1997):  955-9|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32856, 1485, 'Betaxolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32857, 14314, 'Betaxolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32858, 15147, 'Betaxolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32859, 15148, 'Betaxolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32860, 15162, 'Betaxolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32861, 15163, 'Betaxolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32862, 15177, 'Betaxolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32863, 15178, 'Betaxolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32864, 18465, 'Betaxolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32865, 25194, 'Betaxolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32866, 1485, 'Betaxolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32867, 14314, 'Betaxolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32868, 15147, 'Betaxolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32869, 15148, 'Betaxolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32870, 15162, 'Betaxolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32871, 15163, 'Betaxolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32872, 15177, 'Betaxolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32873, 15178, 'Betaxolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32874, 18465, 'Betaxolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32875, 25194, 'Betaxolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', '"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32876, 1485, 'Betaxolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32877, 14314, 'Betaxolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32878, 15147, 'Betaxolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32879, 15148, 'Betaxolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32880, 15162, 'Betaxolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32881, 15163, 'Betaxolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32882, 15177, 'Betaxolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32883, 15178, 'Betaxolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32884, 18465, 'Betaxolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32885, 25194, 'Betaxolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud''s phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984):  333-9|Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982):  109-12|Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985):  1-48|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985):  64-5|Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993):  1188-95|Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud''s phenomenon." Curr Med Res Opin 6 (1979):  267-70|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Uusitalo RJ, Palkama A "Efficacy and safety of timolol pilocarpine combination drops in glaucoma patients." Acta Ophthalmol (Copenh) 72 (1994):  496-504|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991):  s78-81|Edeki TI, He H, Wood AJ "Pharmacogenetic explanation for excessive B-blockade following timolol eye drops." JAMA 274 (1995):  1611-3|Shiuey Y, Eisenberg MJ "Cardiovascular effects of commonly used ophthalmic medications." Clin Cardiol 19 (1996):  5-8|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32886, 1485, 'Betaxolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32887, 14314, 'Betaxolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32888, 15147, 'Betaxolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32889, 15148, 'Betaxolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32890, 15162, 'Betaxolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32891, 15163, 'Betaxolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32892, 15177, 'Betaxolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32893, 15178, 'Betaxolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32894, 18465, 'Betaxolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32895, 25194, 'Betaxolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'Confavreux C, Charles N, Aimard G "Fulminant myasthenia gravis soon after initiation of acebutolol therapy." Eur Neurol 30 (1990):  279-81|Berstein LP, Henkind P "Additional information on adverse reactions to timolol." Am J Ophthalmol 92 (1981):  295-6|Coppeto JR "Timolol-associated myasthenia gravis." Am J Ophthalmol 98 (1984):  244-5|Verkijk A "Worsening of myasthenia gravis with timolol maleate eyedrops." Ann Neurol 17 (1985):  211-2|Herishanu Y, Rosenberg P "Beta-blockers and myasthenia gravis." Ann Intern Med 83 (1975):  834-5|"Product Information. OptiPranolol (metipranolol ophthalmic)." Bausch and Lomb Americas, Inc.  (2022):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Betagan (levobunolol ophthalmic)." Allergan Inc  (2022):|Choi KL, Wat MS, Ip TP, Kung AWC, Lam KSL "Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment." Aust N Z J Med 25 (1995):  257|"Product Information. Betoptic (betaxolol ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Timoptic (timolol ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Betaxon (levobetaxolol ophthalmic)." Alza  (2001):|"Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32896, 69, 'Acitretin', 'Hyperlipidemias', 'Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values.  It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established.  Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions.  Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin.  Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32897, 70, 'Acitretin', 'Hyperlipidemias', 'Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values.  It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established.  Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions.  Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin.  Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32898, 11931, 'Acitretin', 'Hyperlipidemias', 'Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values.  It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established.  Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions.  Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin.  Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32899, 11932, 'Acitretin', 'Hyperlipidemias', 'Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values.  It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established.  Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions.  Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin.  Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32900, 23398, 'Acitretin', 'Hyperlipidemias', 'Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values.  It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established.  Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions.  Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin.  Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32901, 23399, 'Acitretin', 'Hyperlipidemias', 'Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values.  It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established.  Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions.  Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin.  Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32902, 25459, 'Acitretin', 'Hyperlipidemias', 'Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values.  It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established.  Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions.  Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin.  Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32903, 25460, 'Acitretin', 'Hyperlipidemias', 'Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values.  It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established.  Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions.  Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin.  Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32904, 69, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32905, 70, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32906, 11931, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32907, 11932, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32908, 23398, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32909, 23399, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32910, 25459, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32911, 25460, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32912, 69, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32913, 70, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32914, 11931, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32915, 11932, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32916, 23398, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32917, 23399, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32918, 25459, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32919, 25460, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32920, 69, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32921, 70, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32922, 11931, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32923, 11932, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32924, 23398, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32925, 23399, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32926, 25459, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32927, 25460, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32928, 69, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32929, 70, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32930, 11931, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32931, 11932, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32932, 23398, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32933, 23399, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32934, 25459, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32935, 25460, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', '"Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):|"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32936, 69, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32937, 70, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32938, 11931, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32939, 11932, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32940, 23398, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32941, 23399, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32942, 25459, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32943, 25460, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32944, 69, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32945, 70, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32946, 11931, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32947, 11932, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32948, 23398, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32949, 23399, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32950, 25459, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32951, 25460, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32952, 69, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32953, 70, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32954, 11931, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32955, 11932, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32956, 23398, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32957, 23399, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32958, 25459, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32959, 25460, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', '"Product Information. Soriatane (acitretin)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32960, 0, 'Bexarotene', 'Cataract', 'The use of bexarotene may cause new cataracts or worsening of previous cataracts.  It is recommended to monitor closely for the development of any visual difficulties and to have an appropriate ophthalmologic evaluation.  Exercise caution when using this agent in patients with a history of cataracts.', '2', '"Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32961, 0, 'Bexarotene', 'Diabetes Mellitus', 'The use of bexarotene may cause hypoglycemia in diabetic patients.  It is recommended to measure baseline blood glucose levels and to keep monitoring them closely during treatment.  Exercise caution when using this agent in diabetic patients.', '2', '"Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32962, 0, 'Bexarotene', 'Hyperlipidemias', 'The use of bexarotene may cause elevations in lipids.  It is recommended to monitor lipid levels closely and to obtain a fasting blood lipid reading at baseline and weekly until lipid response to the drug is established.  Exercise caution when using this agent in patients with hyperlipidemia.', '2', '"Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32963, 0, 'Bexarotene', 'Hypothyroidism', 'The use of bexarotene may cause hypothyroidism.  It is recommended to consider thyroid hormone supplementation in patients with hypothyroidism, to obtain baseline thyroid function tests, and to closely monitor patients during treatment.', '2', '"Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32964, 0, 'Bexarotene', 'Liver Diseases', 'In vitro studies suggest that cytochrome P450 3A4 is the major cytochrome P450 responsible for formation of the oxidative metabolites and that the oxidative metabolites may be glucuronidated.  It is recommended to monitor for signs of toxicity due to increased drug exposure if bexarotene is used in patients with hepatic impairment as these patients are expected to have a decreased drug clearance.', '2', '"Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32965, 0, 'Bexarotene', 'Neutropenia', 'The use of bexarotene causes neutropenia.  Neutropenia is reversible after dose reduction or discontinuation of treatment.  Care should be exercised in patients at risk.  It is recommended to obtain complete blood counts at baseline and periodically during treatment.', '2', '"Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32966, 0, 'Bexarotene', 'Pancreatitis', 'Pancreatitis, including a fatal case, has occurred in patients receiving bexarotene.  It is recommended to monitor for pancreatitis and to interrupt treatment if pancreatitis is suspected.  Close monitoring is recommended in patients who have risk factors for pancreatitis, such as high alcohol consumption, uncontrolled diabetes or hyperlipidemia, and prior pancreatitis, as these patients might be at greater risk.', '2', '"Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32967, 0, 'Ziconotide', 'Infections', 'The use of ziconotide is contraindicated in patients with any other concomitant treatment or medical condition that would render intrathecal administration hazardous.  Contraindications to the use of intrathecal analgesia include the presence of infection at the microinfusion injection site, uncontrolled bleeding diathesis, and spinal canal obstruction that impairs circulation of cerebrospinal fluid.', '3', '"Product Information. Prialt (ziconotide)." Elan Pharmaceutical/Athena Neurosciences Inc  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32968, 0, 'Ziconotide', 'Psychotic Disorders', 'The use of ziconotide is contraindicated in patients with a preexisting history of psychosis.  Severe psychiatric symptoms and neurological impairment may occur during therapy with ziconotide.  It is recommended to monitor all patients for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness during treatment with ziconotide.  Discontinue therapy with ziconotide in the event of serious neurological or psychiatric signs or symptoms.', '3', '"Product Information. Prialt (ziconotide)." Elan Pharmaceutical/Athena Neurosciences Inc  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32969, 3933, 'Botulinum toxin type A', 'Lactose Intolerance', 'Dysport (brand of abobotulinumtoxinA) may contain trace amounts of cow''s milk protein.  Patients known to be allergic to cow''s milk protein should not be treated with this product.', '3', '"Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32970, 15453, 'Botulinum toxin type A', 'Lactose Intolerance', 'Dysport (brand of abobotulinumtoxinA) may contain trace amounts of cow''s milk protein.  Patients known to be allergic to cow''s milk protein should not be treated with this product.', '3', '"Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32971, 30217, 'Botulinum toxin type A', 'Lactose Intolerance', 'Dysport (brand of abobotulinumtoxinA) may contain trace amounts of cow''s milk protein.  Patients known to be allergic to cow''s milk protein should not be treated with this product.', '3', '"Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32972, 3933, 'Botulinum toxin type A', 'Neuromuscular Diseases', 'Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise.  Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin.  Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise.  Patients treated with botulinum toxin may require immediate medical attention should they develop these complications.  Caution is advised.', '3', '"Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc|"Product Information. Botox (onabotulinumtoxinA)." Allergan Inc|"Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):|"Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32973, 15453, 'Botulinum toxin type A', 'Neuromuscular Diseases', 'Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise.  Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin.  Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise.  Patients treated with botulinum toxin may require immediate medical attention should they develop these complications.  Caution is advised.', '3', '"Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc|"Product Information. Botox (onabotulinumtoxinA)." Allergan Inc|"Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):|"Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32974, 30217, 'Botulinum toxin type A', 'Neuromuscular Diseases', 'Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise.  Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin.  Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise.  Patients treated with botulinum toxin may require immediate medical attention should they develop these complications.  Caution is advised.', '3', '"Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc|"Product Information. Botox (onabotulinumtoxinA)." Allergan Inc|"Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):|"Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32975, 3933, 'Botulinum toxin type A', 'Infections', 'Botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, and others should not be used in the presence of infection at the proposed injection site(s) as it could lead to severe local or disseminated infection(s).', '3', '"Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc|"Product Information. Botox (onabotulinumtoxinA)." Allergan Inc|"Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):|"Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32976, 15453, 'Botulinum toxin type A', 'Infections', 'Botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, and others should not be used in the presence of infection at the proposed injection site(s) as it could lead to severe local or disseminated infection(s).', '3', '"Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc|"Product Information. Botox (onabotulinumtoxinA)." Allergan Inc|"Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):|"Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32977, 30217, 'Botulinum toxin type A', 'Infections', 'Botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, and others should not be used in the presence of infection at the proposed injection site(s) as it could lead to severe local or disseminated infection(s).', '3', '"Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc|"Product Information. Botox (onabotulinumtoxinA)." Allergan Inc|"Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):|"Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32978, 3933, 'Botulinum toxin type A', 'Urinary Tract Infections', 'Botox (brand of onabotulinumtoxinA), a botulinum toxin product for the treatment of overactive bladder or detrusor overactivity associated with a neurologic condition should not be used in patients who have a urinary tract infection, in patients with urinary retention and in patients with post-void residual urine volume >200 mL, who are not routinely performing clean intermittent self-catheterization.', '3', '"Product Information. Botox (onabotulinumtoxinA)." Allergan Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32979, 15453, 'Botulinum toxin type A', 'Urinary Tract Infections', 'Botox (brand of onabotulinumtoxinA), a botulinum toxin product for the treatment of overactive bladder or detrusor overactivity associated with a neurologic condition should not be used in patients who have a urinary tract infection, in patients with urinary retention and in patients with post-void residual urine volume >200 mL, who are not routinely performing clean intermittent self-catheterization.', '3', '"Product Information. Botox (onabotulinumtoxinA)." Allergan Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32980, 30217, 'Botulinum toxin type A', 'Urinary Tract Infections', 'Botox (brand of onabotulinumtoxinA), a botulinum toxin product for the treatment of overactive bladder or detrusor overactivity associated with a neurologic condition should not be used in patients who have a urinary tract infection, in patients with urinary retention and in patients with post-void residual urine volume >200 mL, who are not routinely performing clean intermittent self-catheterization.', '3', '"Product Information. Botox (onabotulinumtoxinA)." Allergan Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32981, 3933, 'Botulinum toxin type A', 'Glaucoma, Angle-Closure', 'Xeomin (brand of incobotulinumtoxinA), a botulinum toxin product for the treatment of blepharospasm should be used with caution in patients at risk of developing narrow angle glaucoma.  The anticholinergic effects of botulinum toxin products can reduce blinking and lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.  To prevent ectropion, it is recommended that botulinum toxin products should not be injected into the medial lower eyelid area.', '2', '"Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32982, 15453, 'Botulinum toxin type A', 'Glaucoma, Angle-Closure', 'Xeomin (brand of incobotulinumtoxinA), a botulinum toxin product for the treatment of blepharospasm should be used with caution in patients at risk of developing narrow angle glaucoma.  The anticholinergic effects of botulinum toxin products can reduce blinking and lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.  To prevent ectropion, it is recommended that botulinum toxin products should not be injected into the medial lower eyelid area.', '2', '"Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32983, 30217, 'Botulinum toxin type A', 'Glaucoma, Angle-Closure', 'Xeomin (brand of incobotulinumtoxinA), a botulinum toxin product for the treatment of blepharospasm should be used with caution in patients at risk of developing narrow angle glaucoma.  The anticholinergic effects of botulinum toxin products can reduce blinking and lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.  To prevent ectropion, it is recommended that botulinum toxin products should not be injected into the medial lower eyelid area.', '2', '"Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32984, 1593, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32985, 1595, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32986, 1598, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32987, 1606, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32988, 1607, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32989, 1609, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32990, 1793, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32991, 2019, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32992, 2973, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32993, 2975, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32994, 2977, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32995, 11893, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32996, 15335, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32997, 15339, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32998, 15340, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32999, 15341, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (33000, 15347, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'Crean PA, Williams DO "Effect of intravenous and oral acebutolol in patients with bundle branch block." Int J Cardiol 10 (1986):  119-26|Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982):  416-9|Treseder AS, Thomas TP "Sinus arrest due to timolol eye drops." Br J Clin Pract 40 (1986):  256-8|"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc  (2002):|"Product Information. Normodyne (labetalol)." Schering Corporation  (2002):|"Product Information. Trandate (labetalol)." Glaxo Wellcome  (2002):|"Product Information. Corgard (nadolol)." Bristol-Myers Squibb  (2002):|"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Blocadren (timolol)." Merck & Co., Inc  (2001):|"Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals  (2001):|"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical  (2001):|"Product Information. Kerlone (betaxolol)." Searle  (2001):|"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals  (2001):|"Product Information. Betapace (sotalol)." Berlex Laboratories  (2001):|"Product Information. Zebeta (bisoprolol)." Lederle Laboratories  (2001):|"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Levatol (penbutolol)." Reed and Carnrick  (2001):|"Product Information. Coreg (carvedilol)." SmithKline Beecham  (2001):|Frishman WH "Carvedilol." N Engl J Med 339 (1998):  1759-65|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals  (2007):', 'DDInter', 0);
